Evidence map›Paper›PMID 35921031›Full record

ArticleApplied biochemistry and biotechnology2022

Exploration of Novel Lichen Compounds as Inhibitors of SARS-CoV-2 Mpro: Ligand-Based Design, Molecular Dynamics, and ADMET Analyses.

Amit Gupta, Niharika Sahu, Ashish P Singh, Vinay Kumar Singh, Suresh C Singh, Vijay J Upadhye, Alen T Mathew, Rajnish Kumar, Rajeshwar P Sinha

Open access · bronzeAbstract read
In one paragraph

Article in Applied biochemistry and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
10.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. A Comprehensive Review on Chemical Structures and Bioactivities ofJournal of fungi (Basel, Switzerland) · 2025
    Review
  5. Article
  6. ComprehensiveCurrent computer-aided drug design · 2025
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Facile synthesis andFuture medicinal chemistry · 2024
    Article
  12. Article
  13. Review
  14. In-silico studies ofInformatics in medicine unlocked · 2023
    Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Amit GuptaLaboratory of Photobiology and Molecular Microbiology, Centre of Advanced Study in Botany, Institute of Science, Banaras Hindu University, Varanasi, 221005, India.ORCID http://orcid.org/0000-0002-2646-1628
Niharika SahuLaboratory of Photobiology and Molecular Microbiology, Centre of Advanced Study in Botany, Institute of Science, Banaras Hindu University, Varanasi, 221005, India.ORCID http://orcid.org/0000-0002-6028-6130
Ashish P SinghLaboratory of Photobiology and Molecular Microbiology, Centre of Advanced Study in Botany, Institute of Science, Banaras Hindu University, Varanasi, 221005, India.ORCID http://orcid.org/0000-0003-1093-4213
Vinay Kumar SinghSchool of Biotechnology, Centre for Bioinformatics, Institute of Science, Banaras Hindu University, Varanasi, 221005, India.ORCID http://orcid.org/0000-0002-5572-0000
Suresh C SinghPathkits Healthcare Pvt. Ltd, Electronic City Sector-18, Gurgaon, 122001, India.ORCID http://orcid.org/0000-0002-5056-7246
Vijay J UpadhyeParul University (Waghodia), Vadodara, 391760, Gujarat, India.ORCID http://orcid.org/0000-0002-8821-1720
Alen T MathewDepartment of Pharmaceutical Engineering and Technology, Indian Institute of Technology (BHU), Varanasi, India.ORCID http://orcid.org/0000-0003-4928-6620
Rajnish KumarDepartment of Pharmaceutical Engineering and Technology, Indian Institute of Technology (BHU), Varanasi, India.ORCID http://orcid.org/0000-0002-7021-6996
Rajeshwar P SinhaLaboratory of Photobiology and Molecular Microbiology, Centre of Advanced Study in Botany, Institute of Science, Banaras Hindu University, Varanasi, 221005, India. rpsinhabhu@gmail.com.ORCID http://orcid.org/0000-0002-0112-6161
Banaras Hindu University · INIndian Institute of Technology BHU · INParul University · INSyneos Health (India) · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the year 2019-2020, the whole world witnessed the spread of a disease called COVID-19 caused by SARS-CoV-2. A number of effective drugs and vaccine has been formulated to combat this outbreak. For the development of anti-COVID-19 drugs, the main protease (Mpro) is considered a key target as it has rare mutations and plays a crucial role in the replication of the SARS CoV-2. In this study, a library of selected lichen compounds was prepared and used for virtual screening against SARS-CoV-2 Mpro using molecular docking, and several hits as potential inhibitors were identified. Remdesivir was used as a standard inhibitor of Mpro for its comparison with the identified hits. Twenty-six compounds were identified as potential hits against Mpro, and these were subjected to in silico ADMET property prediction, and the compounds having favorable properties were selected for further analysis. After manual inspection of their interaction with the binding pocket of Mpro and binding affinity score, four compounds, namely, variolaric acid, cryptostictinolide, gyrophoric acid, and usnic acid, were selected for molecular dynamics study to evaluate the stability of complex. The molecular dynamics results indicated that except cryptostictinolide, all the three compounds made a stable complex with Mpro throughout a 100-ns simulation time period. Among all, usnic acid seems to be more stable and effective against SARS-CoV-2 Mpro. In summary, our findings suggest that usnic acid, variolaric acid, and gyrophoric acid have potential to inhibit SARS-Cov-2 Mpro and act as a lead compounds for the development of antiviral drug candidates against SARS-CoV-2.

Indexed as

COVID-19 Drug TreatmentLichensBenzoatesCysteine EndopeptidasesHumansLigandsMolecular Docking SimulationMolecular Dynamics SimulationProtease InhibitorsSARS-CoV-2Viral Nonstructural ProteinsBenzoatesCysteine Endopeptidasesgyrophoric acidLigandsProtease InhibitorsViral Nonstructural ProteinsDrug likenessMolecular dockingMolecular dynamicsSARS-CoV-2 MproVirtual screening

Identifiers

PMID35921031
PMCPMC9346229
OpenAlexW4289516879

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.